Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective

J Med Econ. 2008;11(2):363-66; author reply 366-70. doi: 10.3111/13696990802113147.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Antineoplastic Agents / economics*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Costs and Cost Analysis
  • Docetaxel
  • Drug Costs
  • Erlotinib Hydrochloride
  • Germany
  • Glutamates / economics*
  • Guanine / analogs & derivatives*
  • Guanine / economics
  • Humans
  • Pemetrexed
  • Protein Kinase Inhibitors / economics*
  • Quinazolines / economics*
  • Taxoids / economics*

Substances

  • Antineoplastic Agents
  • Glutamates
  • Protein Kinase Inhibitors
  • Quinazolines
  • Taxoids
  • Pemetrexed
  • Docetaxel
  • Guanine
  • Erlotinib Hydrochloride